T 0424/21 (Antibody Fc variants/ROCHE GLYCART) vom 08.04.2022
- Europäischer Rechtsprechungsidentifikator
- ECLI:EP:BA:2022:T042421.20220408
- Datum der Entscheidung
- 8. April 2022
- Aktenzeichen
- T 0424/21
- Antrag auf Überprüfung von
- -
- Anmeldenummer
- 12710732.4
- IPC-Klasse
- C07K 16/28C07K 16/00
- Verfahrenssprache
- Englisch
- Verteilung
- Nicht verteilt (D)
- Download
- Entscheidung auf Englisch
- Amtsblattfassungen
- Keine AB-Links gefunden
- Weitere Entscheidungen für diese Akte
- -
- Zusammenfassungen für diese Entscheidung
- -
- Bezeichnung der Anmeldung
- Antibody Fc variants
- Name des Antragstellers
- Roche Glycart AG
- Name des Einsprechenden
- Merck Patent GmbH
- Kammer
- 3.3.04
- Leitsatz
- -
- Relevante Rechtsnormen
- European Patent Convention Art 100(a)European Patent Convention Art 100(b)European Patent Convention Art 100(c)European Patent Convention Art 56Rules of procedure of the Boards of Appeal 2020 Art 013(2)
- Schlagwörter
- Amendments - main request, auxiliary requests 1 to 5: added subject-matter (yes)
Amendments - auxiliary request 6: added subject-matter (no)
Amendment to appeal case - justification by party (yes)
Sufficiency of disclosure - auxiliary request 6 (yes)
Inventive step - auxiliary request 6 (yes) - Orientierungssatz
- 1. If the deletion of dependent claims after notification of a summons to oral proceedings enhances procedural economy by clearly overcoming existing objections without giving rise to any new issues this might constitute cogent reasons justifying exceptional circumstances in the sense of Article 13(2) RPBA 2020.
2. For a first medical use of a substance or composition according to Article 54(4) EPC to be sufficiently disclosed it is not required to show the suitability for each and every disease, but it usually suffices to show that at least one medical use is credibly achieved.
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division with the order to maintain the patent on the basis of claims 1 to 6 of auxiliary request 6, filed with the letter of 21 February 2022, and a description to be adapted thereto.